Skip to main content
. 2016 Jan 28;11(1):e0147682. doi: 10.1371/journal.pone.0147682

Fig 4. Combined blockage of mTOR and MEK pathways reduces cell growth synergistically.

Fig 4

A) CHP-212 and SK-N-AS cells were treated with indicated concentrations of AZD6244, MEK162, Everolimus or AZD8055 or combinations thereof as indicated for 1 hour. Then, cells were lysed and analysed by Western blot. Phosphorylation levels of AKT, ERK and S6 were detected by specific anti-phospho antibodies. Loading was verified by specific antibodies to total AKT, ERK and anti—tubulin. B) CHP-212 cells were treated with indicated concentrations of AZD6244, MEK162 or Everolimus or combinations thereof for 96h. Then, cell growth was measured by Cell Titer Glo. Combination index (CI) values with CalcuSyn Software (Biosoft). C) Same as B) but AZD8055 was used instead of Everolimus. D) SK-N-AS cells were treated with indicated concentrations of AZD6244 or Everolimus or combinations thereof for 96h. Then, cell growth was measured by Cell Titer Glo. E) Same as D) but AZD8055 was used instead of Everolimus.